Delivery Order SPE2DB22D2007-SPE2DB25FJ2JG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and requires completion by June 17, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $11,336.48 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct fulfillment order under AmerisourceBergen's broader contract vehicle with DLA. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $27,454.56 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The contract employs firm fixed price terms with an ultimate completion date of September 16, 2025, and utilizes no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,411.43 under a firm fixed-price contract. The delivery order is non-set-aside and carries an ultimate completion date of September 4, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of June 27, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this order from its corporate office location. This delivery order is issued under the company's broader...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This is a non-set-aside, competitively awarded contract with a firm fixed price ceiling value of $9,793.69 and a completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on July 14, 2025, with a contract ceiling value of $3,662.95. This order is not set-aside and was competitively awarded under a firm fixed-price arrangement, with an ultimate completion date of July 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $23,388.90 to AmerisourceBergen Drug Corp for Actemra 162 mg/0.9 mL syringes with a completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child contract under a larger vehicle. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,094.37. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a task under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $16,453.58. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and no set-aside designation was used in the award. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ2JGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,722.90 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on June 16, 2025, with an ultimate completion date of June 17, 2025. This firm fixed price, competitively awarded contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a substantial portfolio of federal medical procurement contracts, primarily with the Defense Logistics Agency and its Medical Supply Chain. The company supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This contract for Actemra, a prescription immunosuppressant therapy, supports the Defense Health Agency and other federal healthcare systems through AmerisourceBergen's established prime vendor relationship with DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 6/16/25 |